PATENT

Attorney Docket No.: HOGAN-06650

I. IN THE CLAIMS:

Claims 1 - 44 are cancelled.

45. (currently amended) A kit for generating a perioperative genomic profile for a subject, comprising:

- a) reagents eapable of detecting which detect the presence of variant alleles of two or more genes selected from the group consisting of BChE, CYP2D6, F5, F2, CACNAIS, MTHFR, MTR, MTRR, CBS, TNFα and TNFβ; and
- b) instructions for using said kit for generating said perioperative genomic profile for said subject.
- 46. (currently amended) The kit of Claim 45, further comprising a computer readable medium program comprising instructions for using said kit for generating said perioperative genomic profile for said subject.
- 47. (currently amended) The kit of Claim 46, further comprising a computer readable medium-program comprising computer instructions which direct a processor to analyze data derived from use of said reagents.
- 48. (currently amended) The kit of Claim 45, wherein said instructions comprise a decision tree information to optimize perioperative care that, based on at least the presence of variant alleles of two or more genes selected from the group consisting of BChE, CYP2D6, F5, F2, CACNAIS, MTHFR, MTR, MTRR, CBS, TNFα and TNFβ, directs a user to a specific perioperative clinical pathway for said subject.
- 49. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate general anesthesia treatment course of action.

Attorney Docket No.: HOGAN-06650

- 50. (previously presented) The kit of Claim 49, wherein said general anesthesia is an inhalational treatment course of action.
- 51. (previously presented) The kit of Claim 49, wherein said general anesthesia is an intravenous treatment course of action.
- 52. (previously presented) The kit of Claim 49, wherein said general anesthesia is a combined inhalational and intravenous treatment course of action.
- 53. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate regional anesthesia treatment course of action.
- 54. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate combined regional and general treatment course of action.
- 55. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate non-invasive surgery treatment course of action.
- 56. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate invasive surgery treatment course of action.
- 57. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate anesthesia treatment course of action during a medical procedure.
 - 58. (previously presented) The kit of Claim 45, wherein said instructions

describe how said perioperative genomic profile is analyzed in selecting appropriate dosages of analgesic compounds.

- 59. (previously presented) The kit of Claim 54, wherein said instructions describe how said perioperative genomic profile is analyzed to increase the dosage of analgesic compounds metabolized by CYP2D6.
- 60. (previously presented) The kit of Claim 54, wherein said instructions describe how said perioperative genomic profile is analyzed to decrease the dosage of analgesic compounds metabolized by CYP2D6.
- 61. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting appropriate prophylaxis for thrombosis.
- 62. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed to increase prophylaxis for thrombosis mediated by variant alleles of *F5*, *F2*, *MTHFR*, *MTR*, and *CBS*.
- 63. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed to decrease prophylaxis for thrombosis mediated by variant alleles of *F5*, *F2*, *MTHFR*, *MTR*, *MTRR*, and *CBS*.
- 64. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting appropriate monitoring procedures.
- 65. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting pre-operative phenotypic tests and consultations.

PATENT

Attorney Docket No.: HOGAN-06650

66. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in providing a prognosis after an anesthesia treatment course of action.

- 67. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in providing a prognosis after a surgical treatment course of action.
- 68. (previously presented) The kit of Claim 45, wherein said instructions describe how said perioperative genomic profile is analyzed in selecting an appropriate post-operative treatment course of action.
 - 69. canceled
 - 70. canceled
- 71. (currently amended) A perioperative genomic profile kit having component parts capable of being assembled for detecting which detect the presence of variant alleles of two or more genes selected from the group consisting of *BChE*, *CYP2D6*, *F5*, *F2*, *CACNAIS*, *MTHFR*, *MTR*, *MTRR*, *CBS*, *TNF*α and *TNF*β in a subject and thereby providing a subject-specific clinical pathway for said subject, comprising a decision tree information to optimize perioperative care that, based at least on the presence or absence of variant alleles of two or more genes selected from the group consisting of *BChE*, *CYP2D6*, *F5*, *F2*, *CACNAIS*, *MTHFR*, *MTR*, *MTRR*, *CBS*, *TNF*α and *TNF*β measured by said kit, directs a user to a specific clinical pathway of medical intervention for said subject.